BIO updates Wednesday January 30, 2013
Shares of Celsion (NASDAQ: CLSN) were halted in after-hours trading on Wednesday. The company said it would hold a conference call Thursday morning at 8 am to discuss the top-line results from its Phase III HEAT Study with ThermoDox.
The HEAT Study had received a Fast Track designation from the FDA and Orphan Drug status.
Isis Pharmaceuticals (NASDAQ: ISIS) is up big on Wednesday on the approval of KYNAMRO by the FDA.
On Tuesday, the Carlsbad, California firm announced FDA approval of this cholesterol-fighting drug. Specifically, the drug is used to treat homozygous familial hypercholesterolemia (HoFH), a rare condition that prevents patients from being able to remove LDL or “bad” cholesterol from the blood. And “rare” is not an overstatement, as literally one in a million Americans develops this condition, which often results in heart attacks and death before the age of 30.
One-in-a-Million Drug Earns Isis $25 million--Investors may wonder why the approval of a drug that will only benefit one-millionth of the population has caused this stock to spike. The answer lies in the company's partnership with Genzyme, a Sanofi company (NYSE: SNY).
With the approval of KYNAMRO, Genzyme will pay ISIS $25 million. That's more than double ISIS's total third quarter revenues. Accordingly, the stock has risen substantially in trading on Wednesday.
Market Reaction--The FDA approval of KYNAMRO has sent Isis skyward in trading on Wednesday.
After bottoming out below $8 in November, Isis gradually climbed back into double-digits by late December. It continued to increase into January, as well.
Now, after hovering in the $13-14 range over the past three weeks, Isis is above $15 as of this writing. It currently rests at its highest point since mid-September of 2012.
Align Technology, Inc. (NASDAQ: ALGN) today announced that Kenneth B. Arola will step down as vice president, finance and chief financial officer effective March 4, 2013 and will remain an employee of the Company through June 28, 2013.
Align Technology, Inc. (NASDAQ: ALGN) today reported financial results for the fourth quarter and fiscal year ended December 31, 2012.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators announced today the publication of complete study results from a Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it has completed the previously announced underwritten public offering of 60,606,061 shares of its common stock, offered at a price of $0.66 per share.
Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company ("Auxilium"), today announced the closing of its previously announced offering of 1.50% Convertible Senior Notes due 2018 (the "Convertible Notes").
Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 25, 2012, at 9:00 a.m. ET to review fourth quarter and full year 2012 financial results.
Generex Biotechnology Corporation (OTCBB: GNBT) today provided an overview on the early breast cancer competitive status of the lead cancer immunotherapy product, AE37, under development at its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).
IEC Electronics Corp. (NYSE MKT: IEC) announces that the replay of today's annual meeting is now available. Listeners may access the annual meeting webcast and presentation by registering through the Company's webcast link on its home page, www.iec-electronics.com.
Life Technologies Corporation (NASDAQ: LIFE) today announced it will provide a complete laboratory solution to identify an estimated 20,000 human remains found in various mass graves in Libya following the uprising of 2011 and to address missing persons cases from the 42-year regime of Muammar Gaddafi.
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the publication of a paper authored by a research group under the supervision of Prof. Doron Lancet from the Department of Molecular Genetics at the Weizmann Institute of Science describing the analysis and display of a non-redundant compendium of human non-coding RNA genes, which was made available as part of GeneCards® Version 3.09, released November 18, 2012.
LipoScience, Inc. (NASDAQ: LPDX) today announced it has closed its previously announced initial public offering of 5,000,000 shares of common stock at a price to the public of $9.00 per share.
Masimo (NASDAQ: MASI) announced today that it will release fourth quarter and full year 2012 financial results for the period ended December 29, 2012, after the market closes on Thursday, February 14, 2013.
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, reported its first Cellvizio system sales in Japan, the world's second largest healthcare market.
mPhase Technologies, Inc. (OTCBB: XDSL) reported today that it has been issued patent number 8,344,543 from the U.S. Patent & Trademark Office (USPTO) for a Reserve Battery System.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has priced an underwritten sale of common stock in a transaction led by J.P. Morgan Asset Management and involving one other institutional investor.
NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, announced that is has launched a website (www.neurometrix.com/sensus) for the SENSUS Pain Management System.
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $11.40 per share, which was the previous day's closing price.
Novus International Inc., a leading manufacturer of animal nutrition and health products and Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced significant steps forward in their collaboration's progress toward commercializing its suite of next-generation animal nutrition enzymes.
Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin-health systems, and Suneva Medical, Inc., a rapidly growing aesthetics company, jointly announce a partnership to co-distribute ReGenica Facial Rejuvenation Complex.
Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, and the Knight Cancer Institute at Oregon Health & Science University (OHSU), a national leader in translational oncology research, have formed a collaboration to develop more clinically predictive in vitro three dimensional cancer models which will ultimately advance discovery of novel cancer therapeutics.
Oxygen Biotherapeutics, Inc. ("Oxygen") (NASDAQ:OXBT) announced today the Company will be presenting at the 15th Annual BIO CEO & Investor Conference to be held at the Waldorf Astoria Hotel in New York City, February 11-12. Michael Jebsen, President and Chief Financial Officer of Oxygen, will present a corporate overview and update on Monday, February 11 at 9 am EST.
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Caroline Krumel resigned her position as vice president of finance and principal accounting officer effective immediately on January 25th.
RBC Life Sciences, Inc. (OTCQB: RBCL) (the "Company"), has been granted US Patent 8357422, which protects its unique dietary supplement formulation that nutritionally supports cognitive function, learning and remembering.
Rite Aid (NYSE: RAD) is taking on heart disease this February by offering customers basic healthy lifestyle support backed by expert pharmacist counseling and 12-page, full-color Heart Health guides available for free online and at pharmacy counters.
RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that its second Phase 1 study with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and keloids, has been fully enrolled.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2012 financial results on Wednesday, February 6, 2013, after the market closes.
SpectraScience, Inc. (OTCQB: SCIE), a San Diego based medical device company, today announced that in continuation of its distribution and sales efforts in Europe and the Middle East it is demonstrating its WavSTAT4 Optical Biopsy System at the 38th Annual Arab Health 2013 Exhibition and Congress.
Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) regarding projected patent number 8370172, which relates to a system and method for submitting claims for a dispensed medication to a patient by point-of-care physicians.
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced advances for its two lead programs, the Neo-Urinary Conduit™ and Neo-Kidney Augment™.
Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF) (FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has received purchase orders for Verisante Aura™ from the Company's exclusive distributors in Canada and Europe.
Walgreens (NYSE: WAG) (Nasdaq: WAG) subsidiary Take Care Health Systems and Indianapolis-based Community Health Network today announced a clinical collaboration that will facilitate more coordinated health care services, and improve patient access to high-quality, convenient and affordable care throughout Central Indiana.
WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, announced the winners of its 6th annual WuXi PharmaTech Life Science and Chemistry Awards at a ceremony held on January 20, 2013.
